TY  - JOUR
T1  - Pharmaceutical Biotechnology beyond Platform Optimism: A Conceptual Review of Synthetic Biology, Cell Engineering, and Scalable Bioprocessing
A1  - Daniel Kim
A1  - Jihoon Park
A1  - Min-seo Kang
A1  - Hyun-woo Jung
JF  - International Journal of Pharmaceutical Research and Allied Sciences
JO  - Int J Pharm Res Allied Sci
SN  - 2277-3657
Y1  - 2025
VL  - 14
IS  - 3
DO  - 10.51847/tH8PKjjHij
SP  - 22
EP  - 32
N2  - Pharmaceutical biotechnology is increasingly described through the language of platforms: reusable biological parts, programmable cells, automated design cycles, intensified bioprocesses, and adaptable manufacturing systems. This framing captures genuine advances but can also obscure differences between technical reuse, process repeatability, product transferability, and pharmaceutical readiness. This conceptual review examines how platform claims are constructed across synthetic biology, cellular engineering, cell-factory development, cell-free manufacturing, and scalable bioprocessing. It traces core definitions, underlying assumptions, mechanisms, operational boundaries, and unresolved tensions across the selected literature without claiming exhaustive coverage or quantitative comparison. The reviewed evidence indicates that modularity is usually demonstrated at a specific layer—such as a genetic component, pathway, receptor, analytical method, or unit operation—whereas broader transfer across hosts, products, scales, facilities, and therapeutic modalities requires additional evidence. Biological burden, pathway coupling, genetic instability, product-specific quality attributes, process integration, biosafety, and environmental context repeatedly limit simple platform generalization. The review therefore proposes a staged maturity logic that distinguishes reusable components, repeatable workflows, robust process families, product-bounded pharmaceutical platforms, and demonstrated transfer and implementation. Advancement between these stages depends on evidence matched to the claimed layer of maturity rather than on the platform label itself. Priority research should test transfer under predefined biological, process, quality, scale, and use conditions; integrate uncertainty into computational and automated design; and determine when shared infrastructure genuinely preserves product-specific performance. This framework is intended to clarify evidence requirements and research questions, not to provide a validated readiness score or regulatory pathway.
UR  - https://ijpras.com/article/pharmaceutical-biotechnology-beyond-platform-optimism-a-conceptual-review-of-synthetic-biology-cel-3pcmkeg9whdqcag
ER  -